Avalo Therapeutics’ (AVTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Thursday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Several other brokerages also recently issued reports on AVTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. BTIG Research restated a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a report on Monday, September 29th. Finally, Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Avalo Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $32.71.

Avalo Therapeutics Trading Down 3.7%

NASDAQ AVTX opened at $15.06 on Thursday. Avalo Therapeutics has a 12 month low of $3.39 and a 12 month high of $20.72. The stock’s fifty day moving average price is $17.59 and its 200-day moving average price is $13.12. The stock has a market cap of $278.76 million, a P/E ratio of -2.81 and a beta of 0.84.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). As a group, analysts forecast that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avalo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AVTX. Velan Capital Investment Management LP grew its stake in shares of Avalo Therapeutics by 38.4% during the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock valued at $773,000 after purchasing an additional 43,000 shares during the period. Quadrature Capital Ltd bought a new position in shares of Avalo Therapeutics in the 2nd quarter worth approximately $55,000. PFS Partners LLC boosted its holdings in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after buying an additional 1,000 shares during the last quarter. Cantor Fitzgerald L. P. bought a new stake in Avalo Therapeutics during the third quarter valued at approximately $1,083,000. Finally, HighVista Strategies LLC purchased a new stake in Avalo Therapeutics during the third quarter valued at approximately $353,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.